First Time Loading...

Reata Pharmaceuticals Inc
NASDAQ:RETA

Watchlist Manager
Reata Pharmaceuticals Inc Logo
Reata Pharmaceuticals Inc
NASDAQ:RETA
Watchlist
Price: 172.36 USD Market Closed
Updated: Apr 30, 2024

Reata Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Reata Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Reata Pharmaceuticals Inc
NASDAQ:RETA
Revenue
$23.5m
CAGR 3-Years
15%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$81.8B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45B
CAGR 3-Years
2%
CAGR 5-Years
15%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$60.1B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%

Reata Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Reata Pharmaceuticals Inc

Not Available

Breakdown by Segments
Reata Pharmaceuticals Inc

Total Revenue: 2.2m USD
100%
License And Milestone: 1.6m USD
74.4%
Other Revenue: 568k USD
25.6%

See Also

What is Reata Pharmaceuticals Inc's Revenue?
Revenue
23.5m USD

Based on the financial report for Jun 30, 2023, Reata Pharmaceuticals Inc's Revenue amounts to 23.5m USD.

What is Reata Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
-18%

Over the last year, the Revenue growth was 135%. The average annual Revenue growth rates for Reata Pharmaceuticals Inc have been 15% over the past three years , -18% over the past five years .